Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study.
Antirheumatic agents
Interleukin-6
Rheumatoid arthritis
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
09
01
2021
accepted:
10
04
2021
pubmed:
28
4
2021
medline:
12
1
2022
entrez:
27
4
2021
Statut:
ppublish
Résumé
We aimed to investigate the efficacy of anti-IL-6 receptor antibody (aIL-6) and other biologic disease-modifying antirheumatic drugs (bDMARDs), such as TNF inhibitor and CTLA4-Ig in the treatment of rheumatoid arthritis (RA) in patients with knee joint involvement. We retrospectively analyzed 1059 treatment courses of patients with RA who visited our hospitals and were treated with bDMARDs. We categorized them into two groups, with or without knee joint involvement. We investigated the clinical disease activity index (CDAI) at baseline and 12 weeks after the initiation of bDMARDs. We compared the improvement of the markers between aIL-6 and other bDMARDs. Treatment with aIL-6 significantly increased ΔCDAI (n = 91, 15.4 ± 1.1; mean ± SEM) in patients with knee joint involvement, compared to other bDMARDs (n = 232, 11.0 ± 0.7) at 12 weeks (P = 0.006). Following the multivariate analysis adjusted by the CDAI levels at baseline, age, gender, concomitant use of methotrexate, and the first use of bDMARDs, ΔCDAI levels were significantly higher in aIL-6, compared to other bDMARDs (P = 0.02). However, there was no significant difference in ΔCDAI improvement between aIL-6 (n = 162, 5.9 ± 0.6) and other bDMARDs (n = 573, 6.2 ± 0.4) in patients without swollen knee joints. ΔCDAI levels were equally increased in patients with shoulder and elbow joint involvement. aIL-6 was more effective in the patients with RA and knee joint involvement, compared to other bDMARDs.
Identifiants
pubmed: 33903963
doi: 10.1007/s00296-021-04862-y
pii: 10.1007/s00296-021-04862-y
doi:
Substances chimiques
Antirheumatic Agents
0
Biological Products
0
Receptors, Interleukin-6
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1233-1241Références
Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376(9746):1094–1108. https://doi.org/10.1016/s0140-6736(10)60826-4
doi: 10.1016/s0140-6736(10)60826-4
pubmed: 20870100
Maeda Y, Kurakawa T, Umemoto E, Motooka D, Ito Y, Gotoh K et al (2016) Dysbiosis contributes to arthritis development via activation of autoreactive T cells in the intestine. Arthritis Rheumatol 68(11):2646–2661. https://doi.org/10.1002/art.39783
doi: 10.1002/art.39783
pubmed: 27333153
Kishikawa T, Maeda Y, Nii T, Motooka D, Matsumoto Y, Matsushita M et al (2020) Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population. Ann Rheum Dis 79(1):103–111. https://doi.org/10.1136/annrheumdis-2019-215743
doi: 10.1136/annrheumdis-2019-215743
pubmed: 31699813
Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K et al (2014) Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506(7488):376–381. https://doi.org/10.1038/nature12873
doi: 10.1038/nature12873
pubmed: 24390342
pmcid: 24390342
Hashimoto M, Yamazaki T, Hamaguchi M, Morimoto T, Yamori M, Asai K et al (2015) Periodontitis and Porphyromonas gingivalis in preclinical stage of arthritis patients. PLoS ONE 10(4):e0122121. https://doi.org/10.1371/journal.pone.0122121
doi: 10.1371/journal.pone.0122121
pubmed: 25849461
pmcid: 4388350
Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T et al (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66(9):1162–1167. https://doi.org/10.1136/ard.2006.068064
doi: 10.1136/ard.2006.068064
pubmed: 17485422
pmcid: 1955155
Aletaha D, Smolen JS (2018) Diagnosis and management of rheumatoid arthritis: a review. JAMA 320(13):1360–1372. https://doi.org/10.1001/jama.2018.13103
doi: 10.1001/jama.2018.13103
pubmed: 30285183
Narazaki M, Tanaka T, Kishimoto T (2017) The role and therapeutic targeting of IL-6 in rheumatoid arthritis. Expert Rev Clin Immunol 13(6):535–551. https://doi.org/10.1080/1744666x.2017.1295850
doi: 10.1080/1744666x.2017.1295850
pubmed: 28494214
Bijlsma JWJ, Welsing PMJ, Woodworth TG, Middelink LM, Pethö-Schramm A, Bernasconi C et al (2016) Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial. Lancet 388(10042):343–355. https://doi.org/10.1016/s0140-6736(16)30363-4
doi: 10.1016/s0140-6736(16)30363-4
pubmed: 27287832
Linn-Rasker SP, van der Helm-van Mil AH, Breedveld FC, Huizinga TW (2007) Arthritis of the large joints—in particular, the knee—at first presentation is predictive for a high level of radiological destruction of the small joints in rheumatoid arthritis. Ann Rheum Dis 66(5):646–650. https://doi.org/10.1136/ard.2006.066704
doi: 10.1136/ard.2006.066704
pubmed: 17142384
Nakagawa J, Koyama Y, Kawakami A, Ueki Y, Tsukamoto H, Horiuchi T et al (2017) A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study. Arthritis Res Ther 19(1):185. https://doi.org/10.1186/s13075-017-1387-9
doi: 10.1186/s13075-017-1387-9
pubmed: 28800780
pmcid: 5553584
Lansbury J, Haut DD (1956) Quantitation of the manifestations of rheumatoid arthritis. 4. Area of joint surfaces as an index to total joint inflammation and deformity. Am J Med Sci. 232(2):150–155
doi: 10.1097/00000441-195608000-00004
Hashimoto M, Furu M, Yamamoto W, Fujimura T, Hara R, Katayama M et al (2018) Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther 20(1):165. https://doi.org/10.1186/s13075-018-1673-1
doi: 10.1186/s13075-018-1673-1
pubmed: 30075810
pmcid: 6091083
Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K et al (2020) Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study. Arthritis Res Ther 22(1):142. https://doi.org/10.1186/s13075-020-02232-w
doi: 10.1186/s13075-020-02232-w
pubmed: 32539813
pmcid: 7296929
Ebina K, Hirano T, Maeda Y, Yamamoto W, Hashimoto M, Murata K et al (2020) Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis—the ANSWER cohort study. Clin Rheumatol 39(9):2563–2572. https://doi.org/10.1007/s10067-020-05015-5
doi: 10.1007/s10067-020-05015-5
pubmed: 32162152
Jinno S, Onishi A, Dubreuil M, Akashi K, Hashimoto M, Yamamoto W et al (2020) Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort study. Rheumatol Int. https://doi.org/10.1007/s00296-020-04660-y
doi: 10.1007/s00296-020-04660-y
pubmed: 32728836
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324. https://doi.org/10.1002/art.1780310302
doi: 10.1002/art.1780310302
pubmed: 3358796
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581. https://doi.org/10.1002/art.27584
doi: 10.1002/art.27584
Thompson PW, Silman AJ, Kirwan JR, Currey HL (1987) Articular indices of joint inflammation in rheumatoid arthritis. Correlation with the acute-phase response. Arthritis Rheum 30(6):618–623. https://doi.org/10.1002/art.1780300603
doi: 10.1002/art.1780300603
pubmed: 3111490
Lansbury J (1968) Clinical appraisal of the activity index as a measure of rheumatoid activity. Arthritis Rheum 11(4):599–604. https://doi.org/10.1002/art.1780110411
doi: 10.1002/art.1780110411
pubmed: 5302852
Holt I, Cooper RG, Hopkins SJ (1991) Relationships between local inflammation, interleukin-6 concentration and the acute phase protein response in arthritis patients. Eur J Clin Investig 21(5):479–484. https://doi.org/10.1111/j.1365-2362.1991.tb01398.x
doi: 10.1111/j.1365-2362.1991.tb01398.x
Chen DY, Hsieh TY, Chen YM, Hsieh CW, Lan JL, Lin FJ (2009) Proinflammatory cytokine profiles of patients with elderly-onset rheumatoid arthritis: a comparison with younger-onset disease. Gerontology 55(3):250–258. https://doi.org/10.1159/000164393
doi: 10.1159/000164393
pubmed: 18849599
Yoshihara Y, Obata K, Fujimoto N, Yamashita K, Hayakawa T, Shimmei M (1995) Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 38(7):969–975. https://doi.org/10.1002/art.1780380713
doi: 10.1002/art.1780380713
pubmed: 7612046
Sasaki S, Iwata H, Ishiguro N, Obata K, Miura T (1994) Detection of stromelysin in synovial fluid and serum from patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 13(2):228–233. https://doi.org/10.1007/bf02249017
doi: 10.1007/bf02249017
pubmed: 8088064
Gorai M, Ogasawara M, Matsuki Y, Yamada Y, Murayama G, Sugisaki N et al (2014) Weighting with the Lansbury Articular Index improves the correlation of ultrasound score with serum matrix metalloproteinase-3 level in rheumatoid arthritis patients. Mod Rheumatol 24(6):915–919. https://doi.org/10.3109/14397595.2014.888794
doi: 10.3109/14397595.2014.888794
pubmed: 24670135
Lipina M, Makarov M, Makarov S, Novikov A (2017) The degree of cartilage degradation assessed by serum biomarker levels changes after arthroscopic knee synovectomy in rheumatoid arthritis patients. Int Orthop 41(11):2259–2264. https://doi.org/10.1007/s00264-017-3634-8
doi: 10.1007/s00264-017-3634-8
pubmed: 28889180
Kobayashi A, Naito S, Enomoto H, Shiomoi T, Kimura T, Obata K et al (2007) Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis. Arch Pathol Lab Med 131(4):563–570. https://doi.org/10.1043/1543-2165(2007)131[563:Slomms]2.0.Co;2
doi: 10.1043/1543-2165(2007)131[563:Slomms]2.0.Co;2
pubmed: 17425385
Wang J, Devenport J, Low JM, Yu D, Hitraya E (2016) Relationship between baseline and early changes in C-reactive protein and interleukin-6 levels and clinical response to tocilizumab in rheumatoid arthritis. Arthritis Care Res (Hoboken) 68(6):882–885. https://doi.org/10.1002/acr.22765
doi: 10.1002/acr.22765
Zhang W, Doherty M, Peat G, Bierma-Zeinstra MA, Arden NK, Bresnihan B et al (2010) EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis 69(3):483–489. https://doi.org/10.1136/ard.2009.113100
doi: 10.1136/ard.2009.113100
pubmed: 19762361
Hussain SM, Neilly DW, Baliga S, Patil S, Meek R (2016) Knee osteoarthritis: a review of management options. Scott Med J 61(1):7–16. https://doi.org/10.1177/0036933015619588
doi: 10.1177/0036933015619588
pubmed: 27330013